VIKING GLOBAL INVESTORS LP

Viking Global, 10% owner, sold 350,000 shares (77.3% of holdings) at $32.25 for $11.3M on 2025-10-07

Viking Global, a 10% stakeholder in Inhibrx, executed 3 separate sales totaling 350,000 shares for $11,287,500.00 at $32.25 on 2025-10-07, reducing its position from 452,864 shares to 102,864 shares. The current price of $35.00 places the transaction at $2.75 below today's mark, while the stock is -1.8% from its 52-week high of $35.65 and has risen 18.3% over the past 30 days and 60.8% over 90 days. Inhibrx's fundamentals are deteriorating significantly: annual revenue growth is -88.9%, the latest quarterly revenue is $1,300,000.00, net income is -$28,654,000.00, and the P/E ratio stands at 0.31. Across Viking's cross-ticker open-market history, its prior 17 sales averaged a 90-day return of -18.7% with an 82.35% well-timed rate, indicating a pattern of selling before subsequent declines; in this case, however, the stock has appreciated after the transaction, placing this sale outside the insider's typical timing pattern.

Viking Global Investors LP sold 3,500,000 shares of BBIO at $44.00 for $154,000,000; holdings reduced 15.9% to 18.56M shares

Viking Global Investors LP, a 10% owner, executed a large open-market sale of 3,500,000 shares at $44.00 on 2025-06-27, reducing its stake by 15.9% from 22.06M to 18.56M shares. At the time of sale, the stock was trading near recent highs ($44.00 vs. 52-week high of $45.12), and the stock has since declined 5.2% to $42.78, though it remains up 24.9% over the past 30 days and 23.6% over 90 days. While the insider's cross-ticker track record shows strong timing discipline (87.50% of prior sells were well-timed with negative post-trade 90-day returns, averaging -20.6%), the same-ticker history at BBIO is mixed: a prior sell on 2025-01-31 resulted in a 10.0% positive 90-day return, indicating poorly timed execution at that ticker. The company's fundamentals present a contrasting picture—explosive annual revenue growth of 2285.3% sits alongside persistent unprofitability (-$169.6M net income in the latest full fiscal year) on $116.6M quarterly revenue, suggesting a high-growth but cash-consumptive business model that may warrant investor scrutiny of the sustainability and trajectory of burn rates.

Viking Global sold 3,065,616 BBIO shares at $34.90 on Jan 31; retains 22,055,375 shares after -12.2% reduction

Viking Global, a 10% owner, sold 3,065,616 shares (3.07M shares) for $106,989,998.40 ($107.0M), reducing its stake by -12.2% to 22,055,375 shares (22.06M shares) post-transaction. The sale occurred at $34.90 while the company is facing fundamental deterioration: annual revenue growth of -88.0%, a net loss of $-164,254,000.00 ($-164.3M) over the most recent full fiscal year, and latest-quarter revenue of only $2,732,000.00 ($2.7M). Across the insider's entire cross-ticker history, its 15 prior sells showed a 93.33% well-timed rate with an average 90-day return of -22.6%, indicating a strong pattern of selling before downturns. The current price of $34.21 is -12.8% from the 52-week high of $39.23, but the 30-day and 90-day price movements (+24.7% and +34.3% respectively) reflect recent volatility. The significant sale volume combined with the company's severe revenue collapse and unprofitability, paired with the insider's demonstrated pattern of well-timed exits, warrants investor attention to whether this reflects views on the biotech's deteriorating operational trajectory.

Viking Global (10% owner) liquidates entire 1.95M-share stake in APG for $74.5M at $38.15; now holds zero shares.

Viking Global's complete exit represents a material reduction-of-stake transaction: 2 separate sales totaling 1,951,782 shares for $74,460,483.30 at a blended average price of $38.15, reducing holdings from 1.95M shares to zero. The transaction occurred on 2024-06-17 at prices ($38.15) well above the current price of $25.72—a 48.4% discount from the transaction price. Across Viking's prior trades at APG (5 prior trades, distinct from cross-ticker history), all 3 prior measurable sells were well-timed at the 90-day mark, suggesting a pattern of exiting before declines; however, this current filing's timing cannot yet be evaluated (30d and 90d outcomes not yet measurable). The exit coincides with APG trading near its 52-week high of $26.38 and carries material significance given the 10% ownership stake and the complete liquidation of position.

Viking Global Investors LP exits APG completely: 1,951,782 shares sold for $74,460,483.30

Viking Global Investors LP, a 10% owner of APi Group Corp, has completely exited its position through 2 separate sales on 2024-06-17, selling 1,951,782 shares for $74,460,483.30 at an average price of $38.15. This represents a 100% reduction in the holder's stake. The sales occurred at $38.15 while the current price stands at $25.72, representing a significant post-transaction decline of approximately 32.6% from the execution price. Notably, Viking Global's cross-ticker track record shows a 84.62% well-timed rate on 15 prior sells with an average 90-day return of -15.6%, suggesting a pattern of exiting positions before subsequent declines. At the same ticker, prior sales on 2024-03-05 demonstrated -30.2% 90-day returns (well-timed), establishing precedent for skilled timing of APG exits by this holder.